Mounjaro and Zepbound are different brand names for the same molecule: tirzepatide. Eli Lilly markets them under separate brands because regulatory approvals are indication-specific. This article clarifies what actually differs and why the same molecule needs two names.
The shared molecule
Both Mounjaro and Zepbound contain identical tirzepatide — a 39 amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. Same chemical structure, same plasma half-life (~5 days), same mechanism.
Mounjaro — the diabetes indication
| Attribute | Detail |
|---|---|
| Approved indication | Type 2 diabetes (glycaemic control) |
| Route | Subcutaneous, weekly |
| Dose range | 2.5 mg → 5–15 mg weekly |
| Trial programme | SURPASS (diabetes endpoints) |
Zepbound — the obesity indication
| Attribute | Detail |
|---|---|
| Approved indication | Chronic weight management (obesity) |
| Route | Subcutaneous, weekly |
| Dose range | 2.5 mg → 5–15 mg weekly (same as Mounjaro) |
| Trial programme | SURMOUNT (weight-loss endpoints) |
Why two brands for one molecule
The regulatory framework in most countries requires separate marketing authorisations for different indications. Eli Lilly ran the SURPASS trials to support a diabetes indication and the SURMOUNT trials to support an obesity indication. Each trial programme reached its endpoint; each generated a separate regulatory submission; each received a separate brand label.
This is the same logic that gave us Ozempic and Wegovy from semaglutide — same molecule, separate indications, separate brands. See our semaglutide brand article for the parallel pattern.
Dose pathway differences in practice
While the dose range is identical (2.5–15 mg), the titration emphasis differs slightly:
- Mounjaro titration is glycaemic-target driven (move up only if A1c isn’t controlled)
- Zepbound titration is weight-target driven (move up to reach weight-loss goals)
Both follow the same 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg schedule.
Why this matters in research
For research literature analysis:
- SURPASS trial data appears in glycaemic literature under “Mounjaro”
- SURMOUNT trial data appears in obesity literature under “Zepbound”
- Both reference the same tirzepatide molecule
Confusion arises when popular reporting treats them as different drugs. They are not. They are the same molecule with different label indications.
Cost and access differences
In regulated markets, Mounjaro and Zepbound are often priced differently and have different insurance coverage. This is a commercial decision, not a pharmacological one. From a research-material perspective the molecule is identical.
Research handling
Research catalogues list “tirzepatide” — the molecule. Brand names are not used. Chempeptides supplies HPLC-verified tirzepatide with batch CoA — see the catalogue and our tirzepatide mechanism article for protocol depth.
Research use only.